ÂÜÀòÂÒÂ×

Lukas Stanczuk is an experienced scientist specializing in in vivo and in vitro research for preclinical cancer drug discovery and development. Currently serving as Associate Director and previously as Principal Scientist in In Vivo Pharmacology at Bicycle Therapeutics since January 2022, Lukas has held various roles including Senior Scientist at Purespring Therapeutics and Autolus Ltd. Lukas's academic background includes a Ph.D. in Life Sciences from UCL, along with multiple degrees in Biotechnology and Molecular Biology from the University of Warsaw. A postdoctoral researcher at Uppsala University and a former PhD student at Cancer Research UK, Lukas has contributed to understanding the molecular mechanisms of lymphatic system development.